Tecure
Busan, KR Β· 1 known investors
TeCure is a South Korean company developing medical technology aimed at advancing future healthcare. The page provides limited detail about its specific products or services.
Also known as TECURE Β· TeCure, Inc Β· ν°νμ΄
Investors Β· 1
Company profile
researched Aug 2026TeCure, Inc (ν°νμ΄) is a South Korean medical device company headquartered in Haeundae-gu, Busan, that develops precision laser-based endoscopic treatment solutions. Its portfolio spans endoscopic laser devices and catheter products, listed on its site as EsoLight Z360, EndoCure and optical applicators, and it maintains an in-house research laboratory focused on precision laser and next-generation endoscopic treatment technologies.
The company's core technology emits laser light in 360 degrees rather than only in a forward direction. Applied through an endoscope, this is used for precise removal of duodenal mucosa, an approach the company positions as a route toward diabetes treatment. TeCure frames its work around clinical reliability, certification-backed safety, and device usability for both clinicians and patients, and states it is pursuing expansion into global markets.
The company is led by CEO Hyun Wook Kang (κ°νμ±), a professor in the Department of Biomedical Engineering at Pukyong National University, who founded the company. TeCure is a portfolio company of Busan Tech Holdings, the technology holding company commercializing university laboratory research in Busan.
Founding story
TeCure was founded by Professor Hyunwook Kang of the Department of Biomedical Engineering at Pukyong National University, based on laser technology developed in his laboratory that emits light in 360 degrees rather than only forward. The company emerged as a university laboratory technology commercialization case within the Busan Tech Holdings portfolio.
Business model
TeCure develops and commercializes medical devices β endoscopic laser systems, catheters and optical applicators β for use by clinicians in endoscopic procedures, supported by its own research laboratory.
Traction
Selection for Deep Tech TIPS with 1.5 billion KRW in R&D funding; verification of its laser treatment technology through animal testing by company researchers and advisors; recognition as a 2026 Busan Global IP Star Company.
Latest developments
In August 2025 TeCure was reported as recently selected for Deep Tech TIPS, securing 1.5 billion KRW in R&D funding. Company news items report selection as a 2026 Busan Global IP Star Company (May 2026), participation in the Busan "BUNICORN" gathering (April 2026), and participation in KOADMEX 2026 (July 2026).
βΈFull profile β market position, technology, go-to-market, geography
Market position
TeCure is an early-stage university spin-out within the Busan regional startup ecosystem, backed by Busan Tech Holdings, and was selected for Deep Tech TIPS, a Korean government program supporting startups in the country's designated "Top 10 Ultra-Gap Fields."
Rather than forward-only laser emission, TeCure's applicator delivers laser light in a full 360-degree pattern, which the company applies to circumferential endoscopic treatment such as duodenal mucosal removal.
Technology
The company's core technology is a laser emitter that delivers light circumferentially in 360 degrees rather than only forward. Delivered via endoscope and catheter-based optical applicators, it is used for precise removal of duodenal mucosa and for endoscopic treatment of tubular diseases and disorders. Products named by the company include EsoLight Z360, EndoCure and optical applicators. Researchers and advisors have verified the laser treatment technology through animal testing.
Go-to-market
The company participates in industry trade events such as KOADMEX 2026 and works with Busan Tech Holdings on commercialization of laboratory technologies and global expansion strategy, including collaboration with institutions such as Stanford University.
Clinicians and healthcare institutions performing endoscopic procedures; the duodenal mucosal ablation application is directed at diabetes treatment.
Geography
Headquartered at 1203, Ace Hightech 21, 48 Centum Jungang-ro, Haeundae-gu, Busan, South Korea. The company states it is pursuing global market expansion, with global expansion strategy work prepared in collaboration with institutions including Stanford University.
Compiled by commissioned research from 4 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 4
launches, deals, and filingsTeCure was selected for Deep Tech TIPS, a Korean government-private program supporting startups in the "Top 10 Ultra-Gap Fields," securing 1.5 billion KRW in R&D funding. Portfolio company Busan Tech Holdings supported the two-stage technical and market evaluation process.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 4
primary sources listed
- Tecuretecure.com Β· web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Tecure do?
- TeCure is a Busan-based medical device company developing precision laser-based endoscopic treatment systems and catheters.
- Who are Tecure's investors?
- Tecure's investors include Kiwoom Investment.
- Where is Tecure headquartered?
- Tecure is headquartered in Busan, KR.